Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Evotec, PsychoGenics sign CNS drug discovery pact
Under the agreement, the companies will jointly work for providing drug discovery platform to their existing and new clients to identify and develop new therapeutics targeting CNS disorder.
Under the agreement, the companies will jointly work for providing drug discovery platform to their existing and new clients to identify and develop new therapeutics targeting CNS disorder.
BAL30072, a novel siderophore (iron-binding) sulfactam antibiotic, was developed for the patients who were suffering from infections caused by multidrug-resistant Gram-negative bacteria. The Phase I study assessed the
Patanol is indicated for the treatment of the signs and symptoms of allergic conjunctivitis, including itching, redness, chemosis, tearing and lid swelling. The lawsuit was filed following Apotex’s
The results of the trial confirmed that as predicted, KP201 is cleaved in man, releasing the active pharmaceutical compound hydrocodone into the bloodstream at amounts equivalent to the
MuGard is a novel, ready-to-use mucoadhesive oral wound rinse and coating for the management of oral mucositis, a debilitating side effect of many anticancer treatments. eMAX Health Systems
Originally, the licensing agreement was signed between BMS and AMRI in 2005. Under the agreement, AMRI has licensed BMS its technology around central nervous system (CNS) triple reuptake
The company expects to recruit around 900 patients suffering from moderate-to-severe blepharitis in a four-arm trial designed to evaluate both product candidates simultaneously. The efficacy and safety of
The Phase 1 study will evaluate the safety, tolerability, pharmacokinetic profile and antiviral activity of ACH-2684. The trial aims to enroll around 78 healthy subjects and 40 HCV
With this acquisition, Abcam will enhance its manufacturing and product development capability, particularly in the exciting area of assay development. Following the acquisition, the employees of MitoSciences will
Radius products include BA058 Injection and BA058 Microneedle Patch. The BA058 Microneedle Patch uses 3M’s patented Microstructured Transdermal System microneedle technology to administer BA058 through the skin, as